| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-794 | |
| Phytochemical name or plant extracts | Alpinia nantoensis extract | |
| PMID | 31409145 | |
| Literature evidence | Our study strongly supports that the extracts of A nantoensis could be a novel botanical drug lead for the development of an antimetastatic agent for the treatment of human malignant breast cancer. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Ethanolic extract | |
| Source of phytochemicals or plant Extracts | Alpinia nantoensis | |
| Geographical availability | Taiwan | |
| Plant parts | Rhizome, Stem, and Leaves | |
| Other cancers | Breast cancer | |
| Target gene or protein | EGFR | |
| Gene or Protein evidence | We found that the rhizome and leaf extracts from A nantoensis inhibited cell migration, invasion, and sphere formation in MCF-7 and MDA-MB-231 cells. The potency was extended with the inhibition of serum-induced PI3K/AKT and Ras-ERK activation and epidermal growth factor (EGF)-mediated EGFR activation in MDA-MB-231 cells. | |
| Target pathways | PI3K/AKT and Ras-ERK pathways | |
| IC50 | The IC50 values of ANR, ANS, and ANL were 28.13 ± 2.43, 58.04 ± 3.41, 36.05 ± 3.74 µg/mL against MDA-MB-231 42.22 ± 3.17, 164.48 ± 5.49, 47.80 ± 3.79 µg/mL against MCF-7. | |
| Potency | Our study strongly supports that the extracts of A nantoensis could be a novel botanical drug lead for the development of an antimetastatic agent for the treatment of human malignant breast cancer. | |
| Cell line/ mice model | MDA-MB-231, MCF-7 | |
| Additional information | Air-dried rhizome, stem, and leaves of A nantonensis were extracted with ethanol at ambient temperature and concentrated under vacuum to yield the different parts of extract, namely, ANR, ANS, and ANL as rhizome extract, stem extract, and leaves extract, respectively. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:77090126-1 | |
| Safety | NA |